Ignite Creation Date:
2025-12-24 @ 5:07 PM
Ignite Modification Date:
2025-12-24 @ 5:07 PM
Study NCT ID:
NCT04438850
Status:
TERMINATED
Last Update Posted:
2021-06-23
First Post:
2020-04-10
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
COVidIVERmectin: Ivermectin for Treatment of Covid-19
Sponsor:
IRCCS Sacro Cuore Don Calabria di Negrar
Organization:
Study Overview
Official Title:
Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19
Status:
TERMINATED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Incidence has dramatically dropped and there is lack of eligible patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVER
Brief Summary:
Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection.
Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I\_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I\_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres.
In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I\_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I\_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres.
In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Detailed Description:
Primary objectives
The study is aimed:
1. at defining if ivermectin, administered at dosage of 600 μg/kg or 1200 μg/kg QD for five consecutive days is safe in patients with initial, asymptomatic or oligosymptomatic SARS\_CoV-2 infection,
2. at defining if ivermectin, administered at the dosage(s) found to be safe decreases the viral load of SARS-CoV-2 at Day 7.
Secondary objectives To assess
1. the temporal profile of viral load at baseline, day 7, 14 and 30
2. the time to clinical cure (for symptomatic patients)
3. the proportion of patients with virological clearance at day 14 and 30.
4. the hospitalization rate.
5. the COVID-19 Severity Score at day 14 and 30
STUDY DESIGN
This is a multicentre, prospective, randomized, double-blind, adaptive phase II dose finding study.
Patients meeting the inclusion criteria will be asked to participate to the study and randomized in a 1:1:1 ratio to either:
* Placebo arm (arm A): placebo will be identical in appearance to ivermectin in order to preserve blinding and will be administered p.o. at empty stomach with water once daily, for 5 days
* Intervention arms: a) Ivermectin, single dose 600 μg/kg, for 5 days (I\_600) and placebo (arm B) ; b) Ivermectin, single dose 1200 μg/kg, for 5 days (I\_1200) (arm C) ); these drugs will be administered p.o. once daily, for 5 days.
In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Patients will be randomized by a centralized computer system. At randomization a treatment ID is assigned to the patient. Once a treatment ID is assigned this must not be re-assigned even in cases of errors.
Enrolled subjects will be identified by a unique subject number (patient code) that will remain consistent for the duration of the study.
Patients will be recruited at the emergency room of hospitals, and/or among asymptomatic hospital workers found positive for SARS-CoV-2 at routine screening and/or in outpatient ambulatory settings, and/or at home, if not meeting the clinical criteria for hospitalization, according to the routine procedure of each participating site. The expected duration of subject inclusion in the study is of 1 month, or until the planned number of subjects to be enrolled will be reached.
The study is aimed:
1. at defining if ivermectin, administered at dosage of 600 μg/kg or 1200 μg/kg QD for five consecutive days is safe in patients with initial, asymptomatic or oligosymptomatic SARS\_CoV-2 infection,
2. at defining if ivermectin, administered at the dosage(s) found to be safe decreases the viral load of SARS-CoV-2 at Day 7.
Secondary objectives To assess
1. the temporal profile of viral load at baseline, day 7, 14 and 30
2. the time to clinical cure (for symptomatic patients)
3. the proportion of patients with virological clearance at day 14 and 30.
4. the hospitalization rate.
5. the COVID-19 Severity Score at day 14 and 30
STUDY DESIGN
This is a multicentre, prospective, randomized, double-blind, adaptive phase II dose finding study.
Patients meeting the inclusion criteria will be asked to participate to the study and randomized in a 1:1:1 ratio to either:
* Placebo arm (arm A): placebo will be identical in appearance to ivermectin in order to preserve blinding and will be administered p.o. at empty stomach with water once daily, for 5 days
* Intervention arms: a) Ivermectin, single dose 600 μg/kg, for 5 days (I\_600) and placebo (arm B) ; b) Ivermectin, single dose 1200 μg/kg, for 5 days (I\_1200) (arm C) ); these drugs will be administered p.o. once daily, for 5 days.
In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Patients will be randomized by a centralized computer system. At randomization a treatment ID is assigned to the patient. Once a treatment ID is assigned this must not be re-assigned even in cases of errors.
Enrolled subjects will be identified by a unique subject number (patient code) that will remain consistent for the duration of the study.
Patients will be recruited at the emergency room of hospitals, and/or among asymptomatic hospital workers found positive for SARS-CoV-2 at routine screening and/or in outpatient ambulatory settings, and/or at home, if not meeting the clinical criteria for hospitalization, according to the routine procedure of each participating site. The expected duration of subject inclusion in the study is of 1 month, or until the planned number of subjects to be enrolled will be reached.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: